Serum Protein Panel Scoring for Chronic Inflammaging Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers are lacking for chronic inflammation, which is associated with aging and leads to tissue and organ damage, and existing methods to assess immune response do not effectively correlate with non-communicable chronic diseases.
Innovation Solution
A method for measuring systemic chronic inflammaging (SCI) using the levels of CXCL9, TRAIL, IFNG, EOTAXIN, and GROA proteins in blood serum, calculated via a guided auto-encoder algorithm, with kits containing capture agents like monoclonal antibodies for analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional inflammatory biomarkers (IL-6, TNF-α, IL-1β) are measured to assess inflammation, then acute inflammatory responses can be detected, but they fail to accurately measure chronic systemic inflammation associated with aging and non-communicable diseases
Solution Approach 1:
The patent changes the parameters being measured from traditional acute-phase inflammatory markers (IL-6, TNF-α, IL-1β) to a specific panel of proteins including CXCL9, TRAIL, IFNG, EOTAXIN, and GROA that are more indicative of chronic systemic inflammation. This parameter change enables accurate detection of inflammaging and its association with non-communicable chronic diseases
Solution Approach 2:
The patent creates a standardized biomarker panel that replicates the inflammatory profile characteristic of chronic inflammation and aging. By measuring multiple proteins simultaneously and calculating an SCI score, the method produces a reliable copy of the chronic inflammatory state that can be used for diagnosis and treatment monitoring
2Reliability
If standardized biomarkers for chronic inflammation are developed, then accurate measurement of inflammaging is achieved, but currently no such standard biomarkers exist leading to conflicting study results
Solution Approach 1:
The patent segments the complex assessment of chronic inflammation into measurable components by identifying a specific panel of five proteins (CXCL9, TRAIL, IFNG, EOTAXIN, GROA). Each protein is measured individually using established assays, and their combined levels calculate the SCI score, making the complex concept of inflammaging measurable and standardized
Solution Approach 2:
The patent develops a universal biomarker panel that can be applied across different study populations and clinical settings to assess chronic systemic inflammation. The same five-protein panel and SCI scoring method can universally measure inflammaging in diverse cohorts, enabling consistent results across studies
3Measurement precision
If a comprehensive protein panel is measured to capture chronic inflammation, then accurate SCI scoring is achieved, but the measurement and calculation complexity increases
Solution Approach 1:
The patent employs a guided auto-encoder algorithm that automatically processes the protein level measurements and calculates the SCI score without requiring complex manual intervention. The algorithm self-adjusts to weight the contribution of each protein based on its association with chronological age and inflammation, simplifying the calculation process while maintaining precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a standardized biomarker for chronic inflammaging, correlating with cardiovascular disease and comorbidities, aiding in identifying subjects needing treatment and predicting cardiovascular aging.
Implementation Method 1
kits containing capture agents like monoclonal antibodies for analysis
Data Source
AI summary
Provided herein is a method for measuring the levels of chronic inflammaging (SCI) of a subject. In some embodiments, the method may comprise measuring the amount of two or more of the proteins C-X-C motif ligand 9 (CXCL9), TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma (IFNG), eosinophil chemotactic protein (EOTAXIN) and growth-regulated alpha protein (GROA) in a sample (e.g., blood serum) from the subject calculating a score based on the weighted amounts of each of those proteins.